Promising Results in Difficult-to-Treat CLL with Epcoritamab
February 20, 2025
Epcoritamab, a novel bispecific antibody monotherapy, showed strong results in relapsed / refractory high-risk CLL patients.
Epcoritamab, a novel bispecific antibody monotherapy, showed strong results in relapsed / refractory high-risk CLL patients.
CLL Symptoms In science and medicine, information is constantly changing and may become out-of-date as new data emerge. All articles and interviews are informational only, should never be considered medical advice,
Regular blood testing for those with CLL and SLL is an important part of managing the disease, as it can provide valuable insights into your overall health.
Nurse Practitioner Josie Montegaard will present on the basics of CLL, including its biology, the distinction between CLL and SLL, its classification as a chronic disease, symptoms and how it presents, diagnosis and testing, as well as potential causes, including genetic and environmental factors.
In his book, Dr. Nabhan acknowledges the invaluable role care partners play for their loved ones living with CLL and the toll doing so can have.
Blocking the BTK pathway transformed treatment for CLL, but resistance can develop. The BTK degrader destroys it with two-thirds of patients responding.
Combining the new BCL2 inhibitor sonrotoclax with the BTK inhibitor zanubrutinib produced an overall response rate of 97% in relapsed CLL / SLL.
The combination of pirtobrutinib, venetoclax, and rituximab was very effective and produced deep remissions in patients with relapsed / refractory CLL.
People with CLL and SLL are at higher risk of developing infections due to having weakened immune systems.